MedicaidPrior AuthMedium impact
Onivyde (liposomal irinotecan) (Revised)
Humana·LA · Oncology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has updated prior authorization criteria for Onivyde (liposomal irinotecan), a chemotherapy drug for metastatic pancreatic cancer. The policy now allows first-line treatment in combination with oxaliplatin, fluorouracil and leucovorin, in addition to the existing subsequent therapy indication.
Action Required
By September 1, 2025: Prior authorization team must update Onivyde (liposomal irinotecan) prior authorization requirements for Louisiana Medicaid members. Ensure system captures both first-line therapy (with oxaliplatin, fluorouracil, leucovorin) and subsequent therapy (with fluorouracil, leucovorin) indications for metastatic pancreatic adenocarcinoma. Verify monotherapy requests are flagged for denial as excluded indication.